A study to check whether adding RUTI® to standard BCG treatment for high-risk early-stage bladder cancer is safe and how it changes the body’s defenses, with participants randomly receiving RUTI® or a look-alike treatment.

What you commit to

• Study type: Interventional · Phase 1
• Planned participants: 44
• 2 sites in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with high-risk early-stage bladder cancer that has not grown into the muscle. People get standard BCG treatment plus either RUTI® or a look-alike treatment.

Age

18 years or older

Sex

All sexes can join

Disease stage

High-risk non-muscle invasive bladder cancer (NMIBC)

Read by machine on 9 Nov 2026.

Sites (2)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details